Fulgent Genetics Inc

1. 1

   Election of Directors

   ManagementBoard: FOR

   Elect four directors—Ming Hsieh, Linda Dong, Michael Nohaile, Ph.D., and Regina Groves—to one-year terms expiring in 2027.

2. 2

   Ratification of Selection of Independent Registered Public Accounting Firm

   ManagementBoard: FOR

   Ratify the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.

3. 3

   Advisory Vote on Approval of Executive Compensation (Say-on-Pay

   ManagementBoard: FOR

   Non-binding, advisory vote to approve the compensation of the Company’s named executive officers as disclosed in the proxy statement.

4. 4

   Approval of the Fulgent Genetics, Inc. 2026 Equity Incentive Plan

   ManagementBoard: FOR

   Approve the 2026 Equity Incentive Plan to reserve 2,000,000 new shares (with possible additional shares) for equity awards and replace the 2016 Plan.

   More detail

   The proposal requests approval of a new 2026 Equity Incentive Plan to replace the 2016 Plan. Management seeks this authorization to reserve 2,000,000 new shares (with a potential additional 1,500,000 contingent on cancellations) for future equity awards to employees, directors, and consultants. The request is driven by compensation strategy — maintaining competitive equity grants, aligning employee incentives with stockholder interests, and ensuring sufficient share availability for approximately three years of expected grants. The Board notes governance guardrails in the 2026 Plan: no liberal share recycling, no discounted options, no repricing without stockholder approval, minimum one-year vesting (with limited exceptions and a 5% carve-out), limits on director grant values, and claw-back recoupment provisions. These features reduce risk of dilution, prevent opportunistic repricing, and protect tax-qualified status of ISOs. The Board recommends a "FOR" vote, arguing that the plan supports long-term retention and performance alignment, complies with Nasdaq requirements, and will provide tax-favored treatment for eligible options. Potential criticisms include increased equity overhang (projected to rise to ~14.9% if approved), dilution concerns, and executive-friendly provisions for change-of-control vesting. The analytical trade-off for investors is between the need for competitive equity incentives to attract talent and the shareholder dilution and potential for compensation-related governance risks; the plan’s structural limits mitigate some, but not all, of those concerns.

Upcoming shareholder meetings at Fulgent Genetics Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.

When is the Fulgent Genetics Inc 2026 annual meeting?

Fulgent Genetics Inc (FLGT) holds its 2026 annual shareholder meeting on Thursday, May 14, 2026.

What is the record date for the Fulgent Genetics Inc 2026 meeting?

The record date for the Fulgent Genetics Inc 2026 meeting is Friday, March 20, 2026. Shareholders of record on or before that date are eligible to vote.

Who are the director nominees for Fulgent Genetics Inc's 2026 meeting?

The board is presenting 4 director nominees at the Fulgent Genetics Inc 2026 meeting, listed with their independence status and background.

What proposals will shareholders vote on at the Fulgent Genetics Inc 2026 meeting?

Shareholders will vote on 4 proposals at the Fulgent Genetics Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.